21 results
Keyword Docetaxel Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Ogivri (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 12/12/2018,
, 
, Revision: 3, Authorised, Last updated: 18/03/2020
medicines: with paclitaxel or docetaxel, or with another type of medicine … -
List item
Human medicine European public assessment report (EPAR): Trazimera (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 5, Authorised, Last updated: 24/03/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Kanjinti
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 16/05/2018,, , Revision: 6, Authorised, Last updated: 29/11/2019
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Herzuma
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018,, , Revision: 7, Authorised, Last updated: 14/02/2020
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,, Revision: 30, Authorised, Last updated: 30/01/2020
compared with 9.4 months with docetaxel. For squamous NSCLC, a study … months in patients given docetaxel. Supportive information was … -
List item
Human medicine European public assessment report (EPAR): Ontruzant
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, , Revision: 4, Authorised, Last updated: 07/10/2019
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/09/2017,, Revision: 6, Authorised, Last updated: 23/10/2019
Tecentriq is more effective than docetaxel (another cancer medicine … average while those given docetaxel lived for 10 months. In a … 10 months for patients on docetaxel. In another main study of … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,, Revision: 24, Authorised, Last updated: 11/12/2019
another cancer medicine called docetaxel (around 8 months) and the … -
List item
Human medicine European public assessment report (EPAR): Zykadia
ceritinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2015,, Revision: 13, Authorised, Last updated: 12/02/2020
-
List item
Human medicine European public assessment report (EPAR): Xofigo
radium Ra223 dichloride, Prostatic Neoplasms
Date of authorisation: 13/11/2013,
, , Revision: 10, Authorised, Last updated: 10/01/2020
-
List item
Human medicine European public assessment report (EPAR): Zejula
Niraparib (tosylate monohydrate), Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Date of authorisation: 16/11/2017,, 
, Revision: 7, Authorised, Last updated: 14/02/2020
-
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, 
, Revision: 17, Authorised, Last updated: 24/01/2020
-
List item
Human medicine European public assessment report (EPAR): Tagrisso
osimertinib mesylate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, 
, Revision: 9, Authorised, Last updated: 25/02/2020
-
List item
Human medicine European public assessment report (EPAR): Ketoconazole HRA
Ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014,, , , Revision: 10, Authorised, Last updated: 10/01/2020
-
List item
Human medicine European public assessment report (EPAR): Yescarta
axicabtagene ciloleucel, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, , Revision: 4, Authorised, Last updated: 03/02/2020
-
List item
Human medicine European public assessment report (EPAR): Farydak
panobinostat lactate anhydrous, Multiple Myeloma
Date of authorisation: 28/08/2015,, , Revision: 7, Authorised, Last updated: 02/12/2019
-
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib s-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, , Revision: 7, Authorised, Last updated: 13/02/2020
-
List item
Human medicine European public assessment report (EPAR): Provenge
autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor, Prostatic Neoplasms
Date of authorisation: 06/09/2013,, Revision: 1, Withdrawn, Last updated: 19/05/2015
-
List item
Human medicine European public assessment report (EPAR): Ristempa
pegfilgrastim, Neutropenia
Date of authorisation: 13/04/2015,, Revision: 3, Withdrawn, Last updated: 07/03/2018
-
List item
Human medicine European public assessment report (EPAR): Portrazza
necitumumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 15/02/2016,, Revision: 2, Authorised, Last updated: 05/12/2016
-
List item
Human medicine European public assessment report (EPAR): Alecensa
alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 16/02/2017,, Revision: 7, Authorised, Last updated: 14/09/2018